NIAGARA-ON-THE-LAKE, ONTARIO, Canada--(BUSINESS WIRE)--FACTIVE(R) (gemifloxacin mesylate) tablets, Oscient Pharmaceuticals Corporation’s (Nasdaq: OSCI) lead antibiotic product, is the subject of five poster presentations at the Third International Symposium on Resistant Gram-Positive Infections being held in Niagara-on-the-Lake, Ontario, Canada from October 9-11, 2006. This year’s symposium is focused on antibiotic therapy with newer agents, vaccinations and modes of prevention of Gram-positive infections.
